MREO — Mereo BioPharma Share News
0.000.00%
Last trade - 00:00- $44.96m
- $14.85m
- $0.50m
Mereo Biopharma gains on cooperation agreement with largest shareholder
Brief: Mereo Biopharma Reaches Cooperation Agreement With Rubric Capital Management
Mereo gains on U.S. FDA's 'fast track' tag for genetic disorder treatment
Brief: Mereo Biopharma Receives FDA Fast Track Designation For Alvelestat For Treatment Of Alpha-1 Antitrypsin Deficiency (Aatd)-Associated Lung Disease
Brief: Mereo Biopharma Offered To Settle Proxy Contest With Rubric Capital Management
Brief: Mereo BioPharma Reports Clinical Update From Activate Phase 1B/2 Open Label Study Of Etigilimab Plus Nivolumab
Brief: Mereo Biopharma Sends Letter To Rubric Capital Management
Brief: Mereo Biopharma Group Says Sent Letter To Rubric Capital Responding To Letter Dated Aug 19
Brief: Mereo Biopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. STOCKS ON THE MOVE-BuzzFeed, World Wrestling Entertainment, Tesla
U.S. STOCKS ON THE MOVE-Kroger Co, Centene, Snap Inc
U.S. STOCKS ON THE MOVE-Revlon, JD.com, Roku
Mereo Bio jumps on report of possible AstraZeneca bid
Brief: Rubric Capital Management LP Says Delivered A Letter To Mereo Biopharma Group PLC
Brief: Mereo Biopharma To Present Data Update For The Phase 1B/2 Study (Activate) Of Etigilimab And Nivolumab At 2022 Asco Annual Meeting Mereo Also Updates Capital Allocation And Portfolio Prioritization Plan
Brief: Mereo Biopharma Announces The Presentation Of Updated Data From A Phase 1B/2 Study Of Etigilimab As A Poster At The 2022 American Society Of Clinical Oncology Annual Meeting
Brief: Rubric Capital Management Reports 12.82% Stake In Mereo Biopharma Group
Brief: Mereo Biopharma Received Notification Of Nasdaq Minimum Bid Price Deficiency
On May 23, Received Letter From Nasdaq Notifying Co's Adss Failed To Maintain Minimum Bid Price Required By Listing Rules